olivLaw · US equity research
Aurora Cannabis Inc. ACB
Medicinal Chemicals & Botanical Products · SIC 2833 · Vertical: Medicinal Chemicals & Botanical Products (SIC 2833)
Aurora Cannabis Inc. is a Canadian medical cannabis company that files its annual report with the SEC on Form 40-F and is listed on the Toronto Stock Exchange and Nasdaq under the symbol ACB. The filing for the fiscal year ended March 31, 2026 shows an extensive corporate governance framework and significant audit fee commitments.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Aurora Cannabis Inc. (ACB) stock was 5.24 USD (+1.55% on the day), with beta 1.33, 52-week range 2.58–5.57 USD. Latest reported quarter (Q4 2025): net income of -17.2 m USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 78.4
- overbought (≥ 70)
- Bollinger (20, 2)
- 3.49 – 4.95
- above the upper band · %B 1.19 · band width 34.7%
- SMA 50 / 200
- 4.10 / 3.57
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.17 / 0.06
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +17.5% | −1.1% | +18.6 pp | — |
| 3 months | +80.1% | −0.5% | +80.5 pp | — |
| 6 months | +48.0% | +4.4% | +43.6 pp | — |
| Year to date | +24.2% | +12.3% | +11.9 pp | — |
| 1 year | +15.4% | +13.5% | +1.9 pp | −39.5% |
| 3 years | +6.9% | +76.4% | −69.5 pp | −45.3% |
| 5 years | −92.1% | +63.7% | −155.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q4 2025 · 31 Mar 2025
Quarterly statements · CAD
| Fiscal year | Q4 '22 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|
| Gross profit | — | 42.9 m | 42.2 m ≈ | 74.9 m ≈ | 27.6 m |
| Operating income | — | -981.0 k | -2.6 m ≈ | 32.6 m ≈ | -24.0 m |
| Interest expense | — | 1.8 m | 2.2 m ≈ | 2.0 m ≈ | 2.5 m |
| Pre-tax income | — | 5.8 m | 370.0 k ≈ | 27.7 m ≈ | -13.5 m |
| Net income | 0 | 3.8 m | -13.2 m ≈ | 28.2 m ≈ | -17.2 m |
| Diluted EPS | — | 0.10 | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 55.2 m | 245.5 m | 268.7 m | 245.3 m | 221.3 m | 269.6 m | 343.3 m |
| Revenue YoY | unavailable | +344.8% | +9.4% | −8.7% | −9.8% | unavailable | +27.3% |
| Net income | 71.9 m | -293.5 m | -3.3 bn | -692.0 m | -1.7 bn | -69.3 m | 1.6 m |
| Net income YoY | unavailable | −508.0% | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | 0.15 | -0.29 | unavailable | -4.10 | -7.99 | -1.52 | 0.04 |
| Diluted EPS YoY | unavailable | −293.3% | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | 130.3% | -119.5% | -1,221.7% | -282.2% | -776.0% | -25.7% | 0.5% |
| Free cash flow | -218.6 m | -606.5 m | unavailable | -263.7 m | -142.5 m | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Mar 2025
- Cash
- 137.9 m CAD
- Financial debt
- 61.7 m CAD
- Net debt
- -76.2 m CAD
- Equity
- 608.6 m CAD
- Total assets
- 852.7 m CAD
- Debt / equity
- 0.10x
- Current ratio
- 4.31x
- ROE
- 0.3%
- ROA
- 0.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (CAD)
Margins
Income statement · CAD
| Line | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 245.5 m | 268.7 m | 245.3 m | 221.3 m | 269.6 m | 343.3 m | SEC (XBRL)· 18 Jun 2025verified |
| Gross profit | 142.4 m | -19.9 m | -21.6 m | 21.2 m | 131.7 m | 187.6 m | SEC (XBRL)· 18 Jun 2025verified |
| Research & development | 14.8 m | 26.0 m | 11.4 m | 10.4 m | 3.6 m | 3.7 m | SEC (XBRL)· 18 Jun 2025verified |
| Operating income | -318.3 m | -465.8 m | -282.8 m | -231.4 m | -45.1 m | 4.9 m | SEC (XBRL)· 18 Jun 2025verified |
| Depreciation & amortisation | 63.3 m | 67.6 m | 49.2 m | 48.6 m | 12.0 m | 9.1 m | SEC (XBRL)· 18 Jun 2025verified |
| EBITDA | -254.9 m ≈ | -398.2 m ≈ | -233.6 m ≈ | -182.8 m ≈ | -33.1 m ≈ | 14.0 m ≈ | SEC (XBRL)· 18 Jun 2025derived |
| Interest expense | 39.4 m | 76.1 m | 66.4 m | 71.8 m | 13.8 m | 8.4 m | SEC (XBRL)· 18 Jun 2025verified |
| Pre-tax income | -330.6 m | -3.3 bn | -699.8 m | -1.7 bn | -57.6 m | 20.4 m | SEC (XBRL)· 18 Jun 2025verified |
| Income tax | -29.9 m | -82.2 m | -6.3 m | -2.1 m | -554.0 k | 4.6 m | SEC (XBRL)· 18 Jun 2025verified |
| Net income | -293.5 m | -3.3 bn | -692.0 m | -1.7 bn | -69.3 m | 1.6 m | SEC (XBRL)· 18 Jun 2025verified |
| Diluted EPS | -0.29 | — | -4.10 | -7.99 | -1.52 | 0.04 | SEC (XBRL)· 18 Jun 2025verified |
| Weighted average diluted shares | 1.0 bn | — | — | — | 43.2 m | 55.6 m | SEC (XBRL)· 18 Jun 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · CAD
| Line | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 172.7 m | 162.2 m | 421.5 m | 437.8 m | 136.1 m | 137.9 m | SEC (XBRL)· 18 Jun 2025verified |
| Receivables | 103.5 m | 54.1 m | 56.3 m | 47.0 m | 45.4 m | 42.5 m | SEC (XBRL)· 18 Jun 2025verified |
| Inventories | 111.3 m | 135.9 m | 117.5 m | 116.1 m | 143.6 m | 187.9 m | SEC (XBRL)· 18 Jun 2025verified |
| Current assets | 660.6 m | 417.5 m | 665.9 m | 745.1 m | 426.6 m | 478.3 m | SEC (XBRL)· 18 Jun 2025verified |
| Property, plant & equipment, net | 765.6 m | 946.4 m | 606.1 m | 233.5 m | 263.6 m | — | SEC (XBRL)· 20 Jun 2024verified |
| Goodwill | 3.2 bn | 927.9 m | 887.7 m | 0 | 43.2 m | 43.9 m | SEC (XBRL)· 18 Jun 2025verified |
| Intangibles (excl. goodwill) | 688.4 m | 412.3 m | 367.4 m | 70.7 m | 40.9 m | 45.2 m | SEC (XBRL)· 18 Jun 2025verified |
| Total assets | 5.5 bn | 2.8 bn | 2.6 bn | 1.1 bn | 838.7 m | 852.7 m | SEC (XBRL)· 18 Jun 2025verified |
| Accounts payable | 152.9 m | 95.6 m | 57.9 m | 69.9 m | 58.6 m | 73.6 m | SEC (XBRL)· 18 Jun 2025verified |
| Short-term debt | — | — | — | 0 | 52.4 m | 21.5 m | SEC (XBRL)· 18 Jun 2025verified |
| Long-term debt | 127.5 m | 83.7 m | — | 0 | 4.9 m | 40.2 m | SEC (XBRL)· 18 Jun 2025verified |
| Current liabilities | 436.4 m | 272.3 m | 116.4 m | 130.9 m | 124.6 m | 110.9 m | SEC (XBRL)· 18 Jun 2025verified |
| Total liabilities | 1.1 bn | 656.7 m | 567.0 m | 422.0 m | 236.8 m | 244.1 m | SEC (XBRL)· 18 Jun 2025verified |
| Equity | 4.4 bn | 2.1 bn | 2.0 bn | 665.8 m | 601.9 m | 608.6 m | SEC (XBRL)· 18 Jun 2025verified |
| Shares outstanding at year end | 1.0 bn | 115.2 m | 198.1 m | 297.8 m | 54.5 m | 56.2 m | SEC (XBRL)· 18 Jun 2025verified |
Cash flow · CAD
| Line | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -192.2 m | -342.1 m | -210.6 m | -110.3 m | -68.5 m | 16.0 m | SEC (XBRL)· 18 Jun 2025verified |
| Capex | 414.3 m | — | 53.1 m | 32.2 m | — | — | SEC (XBRL)· 21 Sept 2022verified |
| Free cash flow | -606.5 m ≈ | — | -263.7 m ≈ | -142.5 m ≈ | — | — | SEC (XBRL)· 14 Jun 2023derived |
| Investing cash flow | -312.3 m | -245.4 m | -26.9 m | -36.2 m | -3.4 m | -14.3 m | SEC (XBRL)· 18 Jun 2025verified |
| Financing cash flow | 597.5 m | 582.6 m | 522.0 m | 147.8 m | -47.9 m | -116.0 k | SEC (XBRL)· 18 Jun 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 45.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
46% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 45.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 0.7% | 100 (vs peers) | 23% |
| Net margin · Quality | 0.5% | 73 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 15.8% | 100 (on a fixed band) | 18% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | -5.4x | 100 (on a fixed band) | 23% |
| Interest coverage · Balance sheet | 0.6x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 4.3x | 100 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet70/100 · 3/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality90/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
AURORA CANNABIS INC (ACB). Latest full fiscal year: 2025; data up to 2025-03-31.
Figures computed from the financial statements: revenue 343.3 m CAD in 2025; YoY growth 27.3%; net margin 0.5%; ROE 0.3%; net debt/EBITDA -5.4x.
The estimated value range is 0.50–0.69 CAD per share (median of 1 methods, agreement: single method); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 45.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 0.7%
- Net margin: 0.5%
- Revenue CAGR 3Y: 15.8%
- Net debt / EBITDA: -5.4x
- Current ratio: 4.3x
What contradicts it
- Interest coverage: 0.6x
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Medicinal Chemicals & Botanical Products (SIC 2833) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. | 2.2 bn | — | -48.2% | -41.8% | −0.4% | +115% / +109% |
| TLRYTilray Brands, Inc. | 437.5 m | — | -10.4% | -17.1% | +11.5% | −63% / −84% |
| USNAUsana Health Sciences, Inc. | 264.8 m | — | -4.2% | -2.4% | unavailable | −28% / −70% |
| NAGENiagen Bioscience, Inc. | 199.6 m | 21.3 | 13.3% | 8.4% | +29.9% | −63% / +81% |
| MDWDMediwound Ltd. | 182.3 m | — | -63.9% | -140.8% | −16.1% | −21% / +59% |
| FTLFFitlife Brands, Inc. | 76.8 m | 13.1 | 14.1% | 6.2% | +26.4% | −56% / −15% |
| BTMDbiote Corp. | 71.6 m | 11.8 | — | 3.2% | −2.5% | −55% / −75% |
| NAIINatural Alternatives International, Inc. | 24.3 m | — | -35.0% | -14.5% | +9.7% | −70% / −81% |
| MTEXMannatech Inc | 16.7 m | — | -1,490.1% | -6.9% | −8.3% | −8% / −3% |
| BONBon Natural Life Limited | 4.4 m | — | -3.9% | -10.7% | −21.7% | −39% / −99% |
| GLASGlass House Brands Inc. | — | — | -31.2% | -16.3% | −9.4% | −57% / −45% |
| ACBAurora Cannabis Inc | — | — | 0.3% | 0.5% | +27.3% | +15% / +7% |
| SNDLSNDL Inc. | — | — | -1.4% | -1.7% | +2.8% | −20% / −1% |
| IMCCIM Cannabis Corp. | — | — | -1,496.2% | -20.7% | +1.3% | −99% / −99% |
| CGCCanopy Growth Corp | — | — | -39.9% | -79.2% | +5.8% | −36% / −87% |
| CRONCronos Group Inc. | — | — | 6.5% | 39.1% | +24.6% | +42% / +74% |
1- and 3-year price returns: for ACB from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 11 Jun 2026; since then the company filed 6-K (04 Nov 2026), 6-K (03 Nov 2026), 6-K (29 Oct 2026), 6-K (26 Oct 2026), 6-K (14 Oct 2026), 6-K (08 Oct 2026).
In brief
Aurora Cannabis Inc. is a Canadian medical cannabis company that files its annual report with the SEC on Form 40-F and is listed on the Toronto Stock Exchange and Nasdaq under the symbol ACB. The filing for the fiscal year ended March 31, 2026 shows an extensive corporate governance framework and significant audit fee commitments.
SWOT
Strengths
- The company presents medical and regulatory expertise within a federal framework, along with scientific capabilities in genetics and breeding, which can support product differentiation.
- The governance structure includes independent committees and an audit committee with designated financial experts, which can support investor confidence in financial reporting.
- The listing on the Toronto Stock Exchange and Nasdaq gives the company access to two capital markets, which can facilitate funding of operations.
Weaknesses
- The report mentions the dependence of gross margins on the federal reimbursement program, a change to which could reduce the profitability of the business.
- The document includes references to the need to obtain financing on acceptable terms, which indicates sensitivity to capital market conditions.
- The company does not follow certain Nasdaq governance practices, such as quorum and shareholder approval requirements, which could limit protections for some minority shareholders.
Opportunities
- The expanding legalization of medical and consumer cannabis, including in the United States, could open new markets for the company's products.
- The Safari Flower Company acquisition and international expansion could add capacity and revenue if integration proceeds as planned.
- The goal of sustainable profitability and positive free cash flow, if achieved, could strengthen the company's financial position.
Threats
- Legislative and regulatory changes in the cannabis industry could affect the business model and conditions of sale.
- Competition and pricing pressure could reduce market share and margins, particularly if new operators enter the market.
- Risks in integrating acquired businesses and uncertainty about consumer demand in Canada and in export jurisdictions could affect results.
Risks
- Changes to the federal reimbursement programhigh
The changes effective from April 2026 could reduce the company's gross margins, which would directly affect the profitability of the business.
- Access to financinghigh
The document describes the ability to obtain financing on acceptable terms as uncertain. Financing difficulties could limit investment and operations.
- Regulatory changesmedium
Changes to industry legislation, including in export jurisdictions, could affect authorizations and the business model.
- Acquisition integrationmedium
The report mentions the risk that the integration of acquired businesses may not proceed as expected, which could affect the anticipated benefits.
- Competition and pricingmedium
Competition and pricing pressure in the industry could reduce revenue, especially if demand does not grow at the expected pace.
Investment thesis
What would need to be true (bull case)
- If the broader legalization of cannabis translates into higher demand, the company could benefit from its medical expertise and its regulatory advantage.
- If the acquisition and international expansion integrate successfully, they could add capacity and diversify the company's revenue sources.
- If profitability and positive cash flow goals are met, the company's balance sheet could become stronger and less dependent on external financing.
What would break the thesis
- If the change to the reimbursement program reduces margins, the company's profitability could remain under pressure for an extended period.
- If financing becomes more costly or harder to obtain, investment and expansion plans could be postponed.
- If competition intensifies and legislation changes unfavorably, the company's competitive position could be eroded.
What to watch
- Impact of changes to the federal reimbursement program on gross marginQ1 2027
- Guidance for fiscal 2027 and the targets for profitability and cash flow2027
- Progress of the Safari Flower Company integration and results of international expansionnext 10-K
- Access to financing through shelf and ATM programs and ability to raise capital2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 11 Jun 2026; since then the company filed 6-K (04 Nov 2026), 6-K (03 Nov 2026), 6-K (29 Oct 2026), 6-K (26 Oct 2026), 6-K (14 Oct 2026), 6-K (08 Oct 2026).
The business
According to the 40-F, Aurora Cannabis Inc. is a foreign private issuer that files its annual report under the US-Canada multijurisdictional disclosure system (MJDS). The company's shares are listed on the Toronto Stock Exchange and the Nasdaq Capital Market. The report states that the company operates through wholly owned subsidiaries and that its financial statements are presented mainly in Canadian dollars.
The filing describes a governance framework with a Board of Directors and independent committees for nominations and governance, human resources and compensation, and audit. The report states that committee members are independent under Nasdaq standards, and the audit committee has two directors designated as audit committee financial experts.
The report incorporates by reference the audited financial statements, the management's discussion and analysis (MD&A) and the annual information form (AIF) for the year ended March 31, 2026. The independent auditor is Ernst & Young LLP of Vancouver, and audit fees billed for fiscal 2026 are disclosed in the document.
Segments
Medical cannabis business
The 40-F describes the company through its expertise in medical cannabis in Canada and internationally, along with its breeding program and product portfolio. The document also mentions expansion into additional international markets as a growth direction, while detailed figures are presented in the incorporated MD&A.
Consumer business
The report includes, among its forward-looking statements, a reference to winding down the company's consumer business. This indicates that resources are being focused on medical segments and other strategic directions, without the financial impact being detailed in the main 40-F text.
Safari Flower Company acquisition
The document mentions the acquisition of Safari Flower Company among its forward-looking statements, with associated benefits expected for the company's business. Financial details of the transaction are included in the attached financial statements rather than the main text of the report.
Market context
The report refers to the expansion of legalization of medical and consumer markets, including in the United States, as a factor that could support demand. On the other hand, the document mentions changes to the federal reimbursement program effective April 1, 2026, which could influence the company's gross margins.
The report indicates that cannabis product pricing, the level of demand and competition are key factors for the company's performance. The document also mentions possible changes to industry laws and regulations as sources of uncertainty.
Trends
- Broader cannabis legalizationtailwind
The report refers to expectations of increased legalization of medical and consumer markets, including in the United States. If this trend consolidates, it could open new opportunities for the company.
- Changes to the federal reimbursement programheadwind
The document indicates changes to the federal reimbursement program, effective from April 2026, with an impact on expectations for gross margins. This could reduce profitability if revenue per unit declines.
- International expansionmixed
The report mentions expansion into additional international markets as a future growth direction. The effect depends on access to authorizations and regulatory conditions in each country.
- Cost and capital disciplinetailwind
The document includes, among its forward-looking statements, goals related to profitable growth, positive cash flow and prudent capital allocation. If these goals are achieved, they could support the stability of the company's balance sheet.
Competitive position
The report does not explicitly list the company's competitors. The document does mention competition as a risk factor that could affect prices, market share and demand for the company's products in Canada and in export jurisdictions.
The competitive advantages cited in the report include medical and regulatory expertise within a federal framework, as well as scientific expertise in genetics and breeding. The company presents these elements as differentiators, without a quantitative comparison in the 40-F text.
- Other Canadian medical cannabis producers
The report mentions general competition in the industry without naming specific competitors.
- United States cannabis producers
The report mentions the expanding legalization in the United States, which could bring new competitors into the market.
- International medical cannabis operators
The report refers to international markets, where local competition could be relevant to expansion plans.
- Consumer cannabis product suppliers
The report mentions winding down the consumer business, which indicates a withdrawal from this competitive segment.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- David Gabriel (STS): Putem asigura comunicațiile în cazul unui blackout național, fără rețelele operatorilor de telefonie. Am testat acest scenariu în exercițiul AuroraFinancial Intelligence (RO) · 29 Oct 2026 · RO
- Aurora supercomputer powers two of the largest cosmological simulations to datePhys.org · 20 Oct 2026 · EN
- Amazon Acquires DuckLabs and Integrates DuckDB in Amazon Aurora PostgreSQLInfoQ · 17 Oct 2026 · EN
- Un șofer de 21 de ani, care s-a plimbat cu mașina pe plaja Cap Aurora, are de plătit 10.000 de lei, după ce imaginile au ajuns în mediul onlineLibertatea.ro · 13 Oct 2026 · RO
- Amendă de 10.000 de lei pentru că a intrat cu mașina pe o plajă din Cap AuroraG4Media · 13 Oct 2026 · RO
- "Sânt ân față pe avari". A fost găsit șoferul care și-a parcat mașina pe plajă, la Cap Aurora. Cine este și ce amendă a primitAntena 3 CNN · 13 Oct 2026 · RO
- Amenda uriașă primită de tânărul care a condus pe plaja din Cap AuroraAdevărul · 13 Oct 2026 · RO
- Amendă uriașă. Șoferul care a intrat cu maşina pe plaja din Cap Aurora a fost sancționat cu 10.000 de leiDigi24 · 13 Oct 2026 · RO
- Amenda primită de șoferul care a intrat cu maşina pe plaja Cap AuroraHotNews.ro · 13 Oct 2026 · RO
- Amendă de 10.000 de lei pentru că a intrat cu mașina pe o plajă din Cap AuroraMediafax · 13 Oct 2026 · RO
- „Sânt ân faţă pe avari”. Mașină înmatriculată în Bucureşti, filmată pe plaja de la Cap Aurora. Mesaj... - Digi24Digi24 · 11 Oct 2026 · RO
- „Sânt ân faţă pe avari”. Mașină înmatriculată în Bucureşti, filmată pe plaja de la Cap Aurora. Mesaj ironic la adresa şoferuluiDigi24 · 11 Oct 2026 · RO
- Spectacol de lumini pe cerul Finlandei. Aurora boreală a colorat noaptea în verde și roșuAntena 3 CNN · 11 Oct 2026 · RO
- Alertă de furtună geomagnetică pentru 11 octombrie. Aurora boreală este vizibilă în nordul și centrul EuropeiAntena 3 CNN · 10 Oct 2026 · RO
- China-Europe SMILE mission begins operations with first aurora imagesCGTN — World · 30 Sept 2026 · EN
- Massive 41,000-Square-Foot Alaska Aurora Lounge To Join All-New Hawaiian Business Class Lounge By 2028Simple Flying · 29 Sept 2026 · EN
- Stunning: Alaska Airlines Unveils Lie-Flat 737 MAX 10 “Aurora Suites,” Boosts 787 With 46% Premium SeatingSimple Flying · 29 Sept 2026 · EN
- Alaska Airlines unveils premium economy, luxe 'Aurora Suites' and domestic lie-flatsThe Points Guy · 29 Sept 2026 · EN
- AWS Introduces Foreign Key Constraints in Aurora DSQLInfoQ · 28 Sept 2026 · EN
- Autonomous trucking company Aurora looks to accelerate toward profitabilityCNBC — Top News · 22 Sept 2026 · EN
The latest news item in our archive is from 29 Oct 2026; the newest SEC filing is from 04 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)03 Nov 2026
- Current report (foreign issuer)29 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)14 Oct 2026
- Current report (foreign issuer)08 Oct 2026
- Current report (foreign issuer)07 Oct 2026
- Current report (foreign issuer)06 Oct 2026
- Current report (foreign issuer)24 Sept 2026
- Current report (foreign issuer)16 Sept 2026
Sources
- [1] Form 40-F, fiscal year ended 2026-03-31 · SEC / Aurora Cannabis Inc. · 11 Jun 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.